GlassScriptPhysician profile
Brandon D Freel
NPI 1912261694
$1,939.06
in general payments reported to CMS, 2019-2025
19 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $130 · 2021: $73.72 · 2022: $117 · 2023: $692 · 2024: $278 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.83 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $446.91 | 2023-2025 | Veozah |
| Abbvie INC. | $446.90 | 2019-2023 | |
| Hologic Sales and Service, LLC | $295.70 | 2019-2023 | Acessa Provu System, Novasure, Fetal Fibronectin Enzyme Immunoassay |
| Minerva Surgical, INC | $126.23 | 2019-2024 | |
| Lupin INC. | $97.62 | 2019-2020 | |
| Daiichi Sankyo INC. | $83.97 | 2022-2025 | Injectafer |
| Exeltis, USA INC. | $79.24 | 2023-2025 | Slynd |
| Organon LLC | $68.02 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $43.74 | 2023-2024 | Myfembree |
| Myriad Women'S Health, INC. | $37.91 | 2023 | Myrisk |
| Pfizer INC. | $35.82 | 2023-2024 | |
| Roche Diagnostics Corporation | $31.28 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $28.45 | 2023 | Exparel |
| Coopersurgical, INC. | $24.38 | 2025 | Paragard T 380a |
| Lilly USA, LLC | $22.46 | 2025 | Zepbound |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $21.72 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.85 | 2025 | |
| Aspira Women'S Health INC | $16.94 | 2024 | Ova1 |
| Ferring Pharmaceuticals INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Freel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.